lapatinib has been researched along with substance p in 1 studies
Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (substance p) | Trials (substance p) | Recent Studies (post-2010) (substance p) |
---|---|---|---|---|---|
1,919 | 305 | 1,442 | 17,289 | 277 | 2,010 |
Protein | Taxonomy | lapatinib (IC50) | substance p (IC50) |
---|---|---|---|
Substance-P receptor | Rattus norvegicus (Norway rat) | 0.0005 | |
Substance-K receptor | Rattus norvegicus (Norway rat) | 0.2 | |
Substance-K receptor | Homo sapiens (human) | 0.2455 | |
Substance-P receptor | Homo sapiens (human) | 0.0011 | |
Neuromedin-K receptor | Homo sapiens (human) | 0.125 | |
Substance-K receptor | Mesocricetus auratus (golden hamster) | 0.148 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Almendro, V; Ametller, E; Casas, I; Fernández-Nogueira, P; García-Recio, S; Gascón, P; Mayordomo, C; Pastor-Arroyo, EM; Vinyals, L | 1 |
1 other study(ies) available for lapatinib and substance p
Article | Year |
---|---|
Targeting of substance P induces cancer cell death and decreases the steady state of EGFR and Her2.
Topics: Antibodies; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Ligands; Male; Neoplasms; Neurokinin-1 Receptor Antagonists; Piperidines; Prostatic Neoplasms; Quinazolines; Receptor, ErbB-2; Receptors, Neurokinin-1; Signal Transduction; Substance P; Trastuzumab | 2012 |